Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises (NUS) Form 144 filing reports a proposed sale of 9,046 shares of Common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $109,635.71. The shares represent restricted stock that vested under the issuer's registered plan on 04/24/2012 (4,046 shares) and 05/24/2018 (5,000 shares), with cash payment recorded on the respective vesting dates. The filer states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.